Mary-Elizabeth M. Percival, M.D., M.S. and Roland B. Walter, M.D., Ph.D., M.S.
Dr. Percival is Assistant Professor of Medicine, University of Washington School of Medicine, and Assistant Member, Fred Hutchinson Cancer Research Center, and Dr. Walter is Associate Professor of Medicine, University of Washington School of Medicine, and Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Within the past 12 months, Dr. Percival has received clinical trial support from FLXBio and Dr. Walter has been a consultant to Agios Therapeutics, Amphivena Therapeutics, AstraZeneca, Covagen AG, Emergent Biosolutions, Janssen R&D, Pfizer and Seattle Genetics; received clinical trial/lab support from AbbVie, ADC Therapeutics, Amgen, Amphivena Therapeutics, Arog Pharmaceuticals, Celator, Covagen, Pharmcyclics, Seattle Genetics and Stemline Therapeutics; and has ownership interest in Amphivena Therapeutics.
Albert Einstein College of Medicine, CCME staff, and interMDnet staff have nothing to disclose relevant to this activity.
Estimated time to complete:
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine is accredited
by the Accreditation Council for Continuing
Medical Education to provide continuing medical
education for physicians.
Upon completion of this Cyberounds®
, you should be able to:
- Describe standard treatments for newly diagnosed AML for adults of all ages, including induction chemotherapy and allogeneic hematopoietic cell transplantation (HCT);
- List the areas in which new treatments are needed;
- Appreciate the importance of targeted therapies, such as small molecule inhibitors or antibodies, as an adjunct to standard AML treatments.